RNAi

Type: Keyphrase
Name: RNAi
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Ebola-stoked money flowing into Tekmira

14:14 ET | About: Tekmira Pharmaceuticals Corp (TKMR)Shares of thinly-traded Tekmira Pharmaceuticals (TKMR +16.6%) jump on a 3x surge in volume as investors anticipate FDA action to the persistent Ebola outbreak in Africa. The company has an RNAi therapeutic ... [Published Seeking Alpha - 1 hour ago]
First reported 9 hours ago - Updated 8 hours ago - 1 reports

RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars

/PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that ... [Published OSIX News - 9 hours ago]
First reported Jul 29 2014 - Updated 10 hours ago - 2 reports

Silence Therapeutics : Licensee confirms favourable trial outcome

Silence Therapeutics plcLicensee confirms favourable trial outcomeSilence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious ... [Published Investegate - 13 hours ago]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Zeltia announces results for the first half of 2014 with net sales increased by 10% and EBITDA by 12%

 EBITDA amounted to 22 million euro (+12%), despite the increase in R&D expenditure, mainly attributable to the Phase III trial with Aplidin. Net attributable profit amounted to 16.8 million euro (+16%).Madrid, 29 July 2014:Zeltia S.A. is a world-leading ... [Published Noodls - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 2 reports

Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series

, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online “RNAi Roundtables” that it is hosting during July and August. Each event will be webcast live on the Investors section ... [Published Industrial Info Financials - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

New hepatitis drug could be ‘transformational’: CEO

There are twice the number of Hepatitis B patients than hepatitis C patients in the United States, giving some indication of how successful a hepatitis B cure could be.Arrowhead's hepatitis B drug, ARC-520, is an RNAi therapeutic that targets the hepatitis ... [Published CNBC - Jul 29 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality

In the last decade, several screening technologies have been developed that allow for genome‐scale perturbation of gene expression in mammalian cells. These include siRNA, shRNA, gene traps, and more recently CRISPR‐based gene editing technologies. In ... [Published Molecular Systems Biology - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Global Transcriptomics Market 2014-2018

About Transcriptomics and its TypesTranscriptomics studies involve the collection and analysis of transcriptomes of different types of cells or tissues of organism. A transcriptome represents the set of all RNA molecules, which is a small part of the ... [Published Indianapolis Business Journal - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Temporary Epimutations Confer Drug Resistance

Scientists from the Duke University School of Medicine say that they discovered that microorganisms can use a temporary silencing of drug targets, known as epimutations, to gain the benefits of drug resistance without the commitment to permanent mutations. ... [Published Genetic Engineering News - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The analysts screened those events for the 10 that they feel will ... [Published 24/7 Wall St - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Alnylam And Benitec

By Pannobhaso :[Originally published on 6/16/2014]Related Biotechnology, Pharmaceutical and Healthcare NewsAlnylam and BenitecAlnylam (NASDAQ: ALNY ) is a $5.1B company and Benitec Biopharma ( OTCPK:BTEBY ) ( OTCPK:BNIKF ) is a $120M company. Both are ... [Published BioPortfolio - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Patent Office grants Alnylam new claims on its RNAi delivery method

Alnylam ($ALNY) announced July 22 that its intellectual property estate has been strengthened due to the U.S. Patent Office's issuance of a Notice of Allowance for claims in one of its patent applications that covers "chemically modified RNA therapeutics ... [Published Fierce Drug Delivery - Jul 23 2014]

Quotes

...Geert Cauwenbergh , President and CEO of RXi Pharmaceuticals. He added that, "This study is another step forward to bringing our self-delivering (sd-rxRNA ® ) RNAi technology closer to market. We are very excited by everything we have been able to achieve with our compounds, thus far, and we look forward to providing further updates in the near future."
"We are excited about the potential of AtuRNAi in this application and the progression of our IP toward commercial therapeutics." Silence Therapeutics plc
Novartis has already curtailed much of its internal RNAi research efforts, telling FierceBiotech in April that that decision stemmed from "ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow."
"So I think if a therapeutic is able to enable a cure or a functional cure, I think it's going to be transformational from a public health standpoint, but it's also going to create a lot of value" said Anzalone

More Content

All (397) | News (219) | Reports (0) | Blogs (150) | Audio/Video (0) | Fact Sheets (3) | Press Releases (23)
sort by: Date | Relevance
Healthcare Review: Tekmira Pharmaceuticals, Ore... [Published BioMedReports - 57 mins ago]
Ebola-stoked money flowing into Tekmira [Published Seeking Alpha - 1 hour ago]
100 undergraduate students present research [Published University of Kansas - 5 hours ago]
RXi Pharmaceuticals Expands Clinical Program wi... [Published OSIX News - 9 hours ago]
Silence Therapeutics : Licensee confirms favour... [Published Investegate - 13 hours ago]
PGT Inc. (PGTI) is the Top Small-Cap Star for J... [Published Equities.com - 18 hours ago]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - 18 hours ago]
PGT Inc. (PGTI) Leads Small-Cap Stars in Early ... [Published Equities.com - 22 hours ago]
Quark's RNAi treatment misses the mark in a Pha... [Published FierceBiotech - Jul 29 2014]
Zeltia announces results for the first half of ... [Published Noodls - Jul 29 2014]
Alnylam to Host Additional Events in “RNAi Roun... [Published Industrial Info Financials - Jul 29 2014]
Alnylam to Host Additional Events in “RNAi Roun... [Published Business Wire Health News - Jul 29 2014]
New hepatitis drug could be ‘transformational’:... [Published CNBC - Jul 29 2014]
The Good, the Bad, and the Ugly: in search of g... [Published Molecular Systems Biology - Jul 28 2014]
Global Transcriptomics Market 2014-2018 [Published Indianapolis Business Journal - Jul 28 2014]
Temporary Epimutations Confer Drug Resistance [Published Genetic Engineering News - Jul 28 2014]
5 Huge Biotech Catalysts Right Around the Corne... [Published 24/7 Wall St - Jul 28 2014]
Global Drug Delivery in Cancer Report 2014-Tech... [Published Pharmacy Choice - Jul 28 2014]
Scientists discover new, noncommittal mechanism... [Published Medical Xpress - Jul 27 2014]
Drosophila Genetics And Genomics Conference [Published Exhibitions.co.uk - Jul 26 2014]
Alnylam And Benitec [Published BioPortfolio - Jul 25 2014]
Alnylam And Benitec [Published Seeking Alpha - Jul 25 2014]
Short Interest in Arrowhead Research Corp Incre... [Published American Banking News - Jul 25 2014]
Data on Cancer Gene Therapy Discussed by Resear... [Published HispanicBusiness.com - Jul 23 2014]
Researchers Submit Patent Application, "Method ... [Published HispanicBusiness.com - Jul 23 2014]
Global Drug Delivery in Cancer Report 2014-Tech... [Published HispanicBusiness.com - Jul 23 2014]
The Medicines Company's (MDCO) CEO Clive Meanwe... [Published Seeking Alpha - Jul 23 2014]
Research tackles colony collapse [Published Wallowa County Chieftain - Jul 23 2014]
Tekmira anticipates resolution of TKM-Ebola Pha... [Published BioPrepWatch - Jul 23 2014]
Patent Office grants Alnylam new claims on its ... [Published Fierce Drug Delivery - Jul 23 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alnylam to Host Additional Events in “RNAi Roun... [Published Business Wire Health News - Jul 29 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online “RNAi Roundtables” that it is hosting during July and August. ...
Alnylam gets notice of allowance from USPTO for... [Published PBR - News - Jul 23 2014]
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan et al. patent application 13/693,478. ...
Alnylam Receives Notice of Allowance from Unite... [Published Business Wire Health News - Jul 22 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Manoharan ...
149 Publicly funded risk studies on gene techno... [Published GMO Pundit a.k.a. David Tribe - Jul 21 2014]
Current Research Information System Retrieved 149 records TitleAwd YrProp NoInvestigatorInstitutionViewRISK ASSESSMENT FOR INSECT RESISTANCE TO PYRAMIDED BT COTTON20142011-02185Carriere, Y.UNIVERSITY OF ARIZONATUCSON, ARIZONA Brief Full ASSESSING ...
UPDATE - Silence Therapeutics ready to begin cl... [Published Proactiveinvestors United Kingdom website - Jul 16 2014]
---ADDS BROKER RESEARCH & SHARE PRICE--- Silence Therapeutics ( LON:SLN ) has completed the recruitment for its phase IIa trial of Atu027. The drug will be used in conjunction with frontline chemotherapy Gemcitabine on 24 patients in Germany to treat ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Tekmira Provides Update on TKM-Ebola Phase I Cl... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
Tekmira Receives $1.5 Million Milestone Payment [Published GlobeNewswire: Advertising News - Jul 10 2014]
Tekmira Receives Notice of Clinical Hold for TK... [Published GlobeNewswire: Acquisitions News - Jul 03 2014]
Tekmira Initiating Phase I/II Clinical Trial in... [Published GlobeNewswire: Acquisitions News - May 27 2014]
Tekmira Provides Corporate Update and Announces... [Published GlobeNewswire: Acquisitions News - May 14 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.